Holen Sie sich die Stockscreener-App
2.43
3.85%
0.09
Handel nachbörslich:
2.47
0.04
+1.65%
Schlusskurs vom Vortag:
$2.34
Offen:
$2.34
24-Stunden-Volumen:
2.76M
Relative Volume:
0.77
Marktkapitalisierung:
$682.59M
Einnahmen:
$12.87M
Nettoeinkommen (Verlust:
$-114.34M
KGV:
-2.8105
EPS:
-0.8646
Netto-Cashflow:
$-79.23M
1W Leistung:
-0.41%
1M Leistung:
-12.75%
6M Leistung:
+31.35%
1J Leistung:
+12.50%
1-Tages-Spanne:
$2.34
$2.505
1-Wochen-Bereich:
$2.25
$2.505
52-Wochen-Spanne:
$1.05
$3.31
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Firmenname
Taysha Gene Therapies Inc
Sektor
Branche
Telefon
(214) 612-0000
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Vergleichen Sie TSHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
2.43 | 682.59M | 12.87M | -114.34M | -79.23M | -0.8646 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-04-09 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-01 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-03-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-03-01 | Eingeleitet | Wells Fargo | Overweight |
| 2022-02-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | Guggenheim | Buy |
| 2021-07-16 | Eingeleitet | Needham | Buy |
| 2021-06-24 | Eingeleitet | Truist | Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-06-09 | Eingeleitet | Wedbush | Outperform |
| 2021-06-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Fortgesetzt | Jefferies | Buy |
| 2021-02-24 | Eingeleitet | William Blair | Outperform |
| 2021-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-19 | Eingeleitet | Goldman | Buy |
| 2020-10-19 | Eingeleitet | Jefferies | Buy |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten
Taysha Gene Therapies’ SWOT analysis: promising Rett syndrome therapy boosts stock outlook - Investing.com Australia
Taysha Gene Therapies price target maintained at $13 by Cantor Fitzgerald - Investing.com Canada
Taysha gene therapies stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Taysha Gene Therapies (TSHA) Price Target Raised Amid High Trial Success Confidence | TSHA Stock News - GuruFocus
Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $13 From $7, Maintains Overweight Rating - MarketScreener
Needham Reiterates Buy Rating for Taysha Gene Therapies (TSHA) | - GuruFocus
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Li - GuruFocus
Signify Bio’s $15M round advances in situ protein therapeutics - BioWorld MedTech
Kalkine: Taysha Gene Therapies Grants Equity Awards to New Joiners – A Closer Look at FTSE 350 Companies' Global Peers - Kalkine Media
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | TSHA Stock News - GuruFocus
Taysha Gene Therapies (TSHA) Grants Stock Options to New Employees | TSHA Stock News - GuruFocus
Taysha Gene Therapies Grants Stock Options to New Employees Under Inducement Plan - Nasdaq
Gene Therapy Leader Taysha Awards Massive 401K Share Options Package to Key New Executives - Stock Titan
Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com
Taysha Gene Therapies Stock (TSHA): Innovative Gene Therapy Focus - Value The Markets
Taysha Gene Therapies Releases TSHA-102 Clinical Program Updates - Insider Monkey
Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data - MSN
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Purchased by ProShare Advisors LLC - Defense World
BNP Paribas Financial Markets Acquires New Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Jane Street Group LLC Acquires 62,003 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Given New $11.00 Price Target at Canaccord Genuity Group - Defense World
Taysha reports progress in Rett syndrome gene therapy trials By Investing.com - Investing.com South Africa
Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data By Stocktwits - Investing.com India
taysha gene therapies increases authorized shares to 700 million By Investing.com - Investing.com Nigeria
Taysha Gene Therapies (TSHA) Advances TSHA-102 Program for Rett - GuruFocus
Taysha Gene Therapies Announces Details for Oral Presentations a - GuruFocus
Taysha reports progress in Rett syndrome gene therapy trials - Investing.com
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program - The Manila Times
Taysha Gene Therapies Announces Details For Oral Presentations - marketscreener.com
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program | TSHA Stock News - GuruFocus
Taysha Gene Therapies Announces Details for Oral - GlobeNewswire
Needham Lifts Taysha Gene Therapies (TSHA) PT to $8, Cites Positive Clinical Data - Insider Monkey
Taysha Gene Therapies’ (TSHA) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Taysha Gene Therapies (TSHA) Target Price Raised by Canaccord Ge - GuruFocus
Taysha Gene Therapies (TSHA) Price Target Raised by Canaccord | - GuruFocus
taysha gene therapies increases authorized shares to 700 million - Investing.com
Taysha Gene Therapies Approves Share Increase Amendment - TipRanks
Taysha Gene Therapies (TSHA) Price Target Raised by Canaccord | TSHA Stock News - GuruFocus
Positive Outlook for Taysha Gene Therapies: Buy Rating on Promising TSHA-102 Advancements - TipRanks
Taysha Gene Therapies (TSHA) Updates Clinical Progress in Rett S - GuruFocus
Where Taysha Gene Therapies Stands With Analysts - Benzinga
Needham Adjusts Taysha Gene Therapies Price Target to $8 From $6, Maintains Buy Rating - marketscreener.com
Taysha Gene Therapies (TSHA) Sees Increased Price Target by Needham | TSHA Stock News - GuruFocus
Needham Increases Price Target for Taysha Gene Therapies (TSHA) to $8 | TSHA Stock News - GuruFocus
Taysha Gene Therapies (TSHA) Price Target Raised by JMP on Positive Rett Syndrome Trial Data - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stake Lessened by Deutsche Bank AG - Defense World
Bank of America Corp DE Boosts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):